Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active then Sham Treatment Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Nerve Stimulation Using a TENS to Provide Pain Relief During Surgery for Overactive Bladder

NCT05330117
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder, Pain, Acute
Interventions
TENS, Control TENS
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 4 Interventional

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

NCT01893996
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
Jonathan Graf
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 3 Interventional

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

NCT00998218
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Arrythmias
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Aspirus Heart and Vascular Institute-Research and Education
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wausau, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

NCT02338999
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
PET/CT, Pioglitazone, Placebo
Radiation · Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 15, 2026, 9:27 AM EDT
Recruiting Not applicable Interventional

Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

NCT05102929
View directory record Official record
Conditions
Schizophrenia
Interventions
active intermittent Theta Burst Stimulation (iTBS), sham intermittent Theta Burst Stimulation (iTBS)
Device
Lead sponsor
Fabio Ferrarelli
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

NCT04927975
View directory record Official record
Conditions
Non-Segmental Vitiligo
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Irvine, California • Redwood City, California • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 15, 2026, 9:27 AM EDT
Terminated Not applicable Interventional Results available

Models of Auditory Hallucination

NCT04210557
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Auditory Hallucination
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 15, 2026, 9:27 AM EDT
Not yet recruiting Early Phase 1 Interventional

Cholinergic Enhancement of Theta

NCT07228338
View directory record Official record
Conditions
Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorder, Memory Loss
Interventions
COBENFY KarXT (50/20 mg), Control
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

NCT04435847
View directory record Official record
Conditions
Male Pattern Hair Loss
Interventions
HST 001, Phosphate Buffered Saline
Biological · Other
Lead sponsor
Histogen
Industry
Eligibility
25 Years to 55 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

NCT02471144
View directory record Official record
Conditions
Chronic Severe Plaque-type Psoriasis
Interventions
Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 15, 2026, 9:27 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

NCT06544733
View directory record Official record
Conditions
HIV-1-Infection
Interventions
Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
35
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 15, 2026, 9:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Intravenous Estrogen in Kidney Transplant Study

NCT03663543
View directory record Official record
Conditions
Ischemia Reperfusion Injury
Interventions
Conjugated Estrogen, Normal saline
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 15, 2026, 9:27 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT01156051
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
Interventions
Guanfacine extended-release tablets, Placebo comparator
Drug
Lead sponsor
Children's Specialized Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Hamilton, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Results available

Minocycline and Tobacco Craving in Smokers With Schizophrenia

NCT02968602
View directory record Official record
Conditions
Schizophrenia, Tobacco Use
Interventions
Minocycline, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine (NAC) for Children With Tourette Syndrome

NCT01172288
View directory record Official record
Conditions
Tourettes Syndrome, Tic
Interventions
N-Acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 15, 2026, 9:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Control of Gait & Navigation in ADRD

NCT06501820
View directory record Official record
Conditions
Aging
Interventions
Transcranial direct current stimulation
Device
Lead sponsor
University of Florida
Other
Eligibility
65 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Indomethacin in Chronic Pancreatitis

NCT04207060
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

NCT02145182
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 15, 2026, 9:27 AM EDT
Recruiting Phase 3 Interventional

Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

NCT05206955
View directory record Official record
Conditions
Fontan Palliation
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Results available

Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

NCT02682901
View directory record Official record
Conditions
Diabetic Autonomic Neuropathy
Interventions
Cycloset, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

NCT01882439
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT02579239
View directory record Official record
Conditions
Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy
Interventions
ATYR1940, Placebo
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Irvine, California • Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets

NCT03432572
View directory record Official record
Conditions
Ureteral Injury
Interventions
Pyridium, Riboflavin, Thiamine
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 15, 2026, 9:27 AM EDT